Intrahepatic Cholestasis

The FDA has approved Mirum Pharmaceuticals’ Livmarli oral solution for treatment of cholestatic pruritus in patients aged 5 years and older with progressive familial intrahepatic cholestasis, according to a company release.

Women with intrahepatic cholestasis of pregnancy delivered earlier and had a lower percentage of stillbirths compared with women without the liver disorder, researchers reported in the American Journal of Obstetrics & Gynecology.

WASHINGTON — In a Healio video exclusive, Alexander G. Miethke, MD, noted that Livmarli demonstrated significant reductions in pruritus and serum bile acids across multiple subtypes of progressive familial intrahepatic cholestasis.

Albireo Pharma Inc. announced the publication of the PICTURE study, which assessed the impact that progressive familial intrahepatic cholestasis has on caregivers, according to a company press release.

Odevixibat treatment reduced levels of peripheral blood autotaxin, pruritus and serum bile acid among pediatric patients with progressive familial intrahepatic cholestasis, according to pooled data.

Albiero Pharma Inc. announced it received FDA approval for Bylvay to treat pruritus in all subtypes of progressive familial intrahepatic cholestasis.

In a video exclusive, Lorenzo D’Antiga, MD, Pappa Giovanni XXIII Hospital, said Bylvay induced a sustained improvement in cholestasis-related parameters in patients with progressive familial intrahepatic cholestasis.

In this exclusive video, Richard Thompson, MD, PhD, discussed results from two abstracts presented at The Liver Meeting Digital Experience on using odevixibat in progressive familial intrahepatic cholestasis.